At the news
? BULLISHIMPACT 7/10 PRESS-RELEASE filed Apr 13, 2026 at 06:30 ET
Regeneron and Telix announced a collaboration to co-develop and co-commercialize next-generation radiopharmaceutical therapies, with Regeneron paying $40 million upfront for access to four initial programs. The 50/50 cost and profit-sharing model marks Regeneron's strategic entry into radiopharmaceuticals, combining its antibody expertise with Telix’s radiopharmaceutical infrastructure.
- Regeneron pays Telix $40 million upfront for four initial radiopharmaceutical programs.
- Partnership operates under a 50/50 cost and profit-sharing model, with co-development and co-commercialization rights.
- Telix retains option to opt-out of co-funding and instead receive up to $535 million per program in milestones plus low double-digit royalties.
- Regeneron gains option to expand the collaboration to four additional programs with further upfront payments.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access